Friday, July 10, 2026

pharma · Cancer on the prostatic bed · Prostate cancer at risk of developing metastatic lesions

A.C.O.M. - Advanced

A.C.O.M. - Advanced is a pharma organization headquartered in EU. Primary therapeutic focus areas include Cancer on the prostatic bed, Prostate cancer at risk of developing metastatic lesions. NovaPharmaNews links 2 clin

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
2
Drugs
4
Patents
1
Clinical program

64Cu(II)Cl2 solution for injection

Phase 3 · small molecule · Cancer on the prostatic bed

64Cu(II)Cl2 solution for injection for Cancer on the prostatic bed is a Phase 3 program (small_molecule) at A.C.O.M. - Advanced Center Oncology with 1 ClinicalTrials.gov record(s).

Internal code P.64Cu.002.02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
A.C.O.M. - Advanced Center Oncology
Phase
Phase 3
Modality
small_molecule
Indication
Cancer on the prostatic bed
Status
active
Trials
1